A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union–sourced Herceptin

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 337 citations

Hannah Study, Breast Oncology, Oncology +6

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

Brian Leyland‐Jones, Karen A. Gelmon, Jean-Pierre Ayoub et al. · Journal of Clinical Oncology · 2003 · 295 citations

Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer

René Bruno, Carla Washington, Jianfeng Lü et al. · Cancer Chemotherapy and Pharmacology · 2005 · 242 citations

Breast Oncology, Oncology, Pharmacology +6

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

Hope S. Rugo, Abhijit Barve, Cornelius F. Waller et al. · JAMA · 2016 · 142 citations · Full text

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

Seokkyun Kim, Jinsu Song, Seung-Kyu Park et al. · mAbs · 2017 · 129 citations · Full text

Engineering, Reference Product, Immunology +17